PharmaGap Completes Initial Closing of Private Placement
November 28 2011 - 3:48PM
Marketwired
PharmaGap Inc. (TSX VENTURE:GAP) (OTCBB:PHRGF) ("PharmaGap" or "the
Company") announced today that it has completed the conditional
closing of a private offering of up to 10,000,000 equity units (the
"Units") for a net aggregate amount (if fully subscribed) of up to
$700,000. A total of 971,428 units have been subscribed in this
conditional closing at a price of $0.07 per Unit, for gross
proceeds of $68,000. The Company has been advised of additional
subscriptions for this placement and anticipates completing these
orders in due course.
Each Unit consists of one common share and one warrant to
purchase one common share at an exercise price of $0.10 per common
share with a three year warrant term. The conditional closing of
this private placement is subject to the approval of the TSX
Venture Exchange and the shares and warrants issued pursuant to the
private placement are restricted from trading for four months from
the date of closing.
In connection with this conditional closing, $4,080 in cash fees
will be paid to individuals dealing at arm's length with PharmaGap
as finder's fees.
About PharmaGap Inc.
PharmaGap Inc. (TSX VENTURE:GAP), based in Ottawa, ON, is a
biotechnology company with a core focus on developing novel peptide
therapeutics for the treatment of cancer. PharmaGap's GAP-107B8 is
a novel peptide drug that has been shown to be effective in
numerous cancer types, including chemo-resistant cancers, in vitro.
For more information on PharmaGap please visit the Company's
website at www.pharmagap.com.
Forward Looking Statements
This news release contains certain statements that constitute
forward-looking statements as they relate to the Company and its
management. Forward-looking statements are not historical facts but
represent management's current expectations of future events, and
can be identified by words such as "believe", "expects", "will",
"intends", "plans", "projects", "anticipates", "estimates",
"continues", and similar expressions. Although management believes
that expectations represented in such forward-looking statements
are reasonable, there can be no assurance that they will prove to
be correct.
By their nature, forward-looking statements include assumptions
and are subject to inherent risks and uncertainties that could
cause actual future results, conditions, actions or events to
differ materially from those in the forward-looking statements. If
and when forward-looking statements are set out in this news
release, PharmaGap will also set out the material risk factors or
assumptions used to develop the forward-looking statements. Except
as expressly required by applicable securities laws, the Company
assumes no obligation to update or revise any forward-looking
statements. The future outcomes that relate to forward-looking
statements may be influenced by many factors, including, but not
limited to: results of ongoing product testing and development;
regulatory approvals required to complete development of products;
ability to manufacture product at quality and scale for human use
on an economically sound basis; patient reimbursement by private
and public health insurance programs; unintended side effects of
products; competitive products; product liability; intellectual
property; reliance on key personnel; risks of future legal
proceedings; income tax matters; availability and terms of
financing; distribution of securities; effect of market interest
rates on price of securities, and potential dilution.
Note: Neither the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release. No Securities Commission or other
regulatory authority having jurisdiction over PharmaGap has
approved or disapproved of the information contained herein. This
release contains forward looking statements that may not occur or
may change materially.
Contacts: PharmaGap Inc. Robert McInnis President & CEO
613-990-9551bmcinnis@pharmagap.com
Pharmagap Inc. (TSXV:GAP)
Historical Stock Chart
From May 2024 to Jun 2024
Pharmagap Inc. (TSXV:GAP)
Historical Stock Chart
From Jun 2023 to Jun 2024